top of page
OXY-ELGAN Trial Logo.jpg

OXY-ELGAN-Trial

Does the use of 100% vs 30% oxygen reduce incidence of emergency intubation in the delivery room in 21+0-25+6 week preterm infants? 

Population

Preterm infants born at 21+0-25+6 weeks’ gestation

Primary Objective

Does resuscitation with 100% versus 30% initial oxygen reduce the incidence of emergency intubation in the delivery room in preterm infants (21+0-25+6 weeks’ gestation)?

Primary Hypothesis: Population (P), Intervention (I), Comparison (C), Outcome (O), Timeline (T):  

P: In preterm infants born at 21+0-25+6 weeks’ gestation   

I: does initiating resuscitation with a higher oxygen concentration of 100%

C: compared to initiating with a lower oxygen concentration of 30%

O: increase or decrease the incidence of emergency intubation in the delivery room 

T: within the 1st 30 minutes  after birth?  

Design and Sample Size

This prospective unmasked randomized controlled trial (RCT) comparing two oxygen concentrations at initiation of resuscitation. 50 - 25 control / 25 intervention

Inclusion Criteria

i) Infants with gestational age between 21+0-25+6 weeks based on best available obstetrical estimate, requiring respiratory support

ii) Infants designated to receive full resuscitation, i.e., no parental request or pre-determined decision to provide only comfort care at birth

iii) No known major congenital or chromosomal malformation.

Exclusion Criteria 

i) Infant born outside of study centers and transported to centers after delivery.

Efficacy Endpoints 

Primary:

  • incidence of emergency intubation in the delivery room within 30 minutes after birth

Secondary: 

  • Delivery room interventions

  • Admission temperature

  • Neonatal UTSTEIN

  • Mechanical ventilation

  • Infection/sepsis

  • Pneumothorax

  • Brain injury as indicated by abnormal neuroimaging

  • among others

Safety Evaluations 

Adverse events

Statistical Methodology

The final analysis will be conducted after the study is completed, unblinded, and the database is released for analysis.

Clinical Center:

Royal Alexandra Hospital, Canada

Enrolment Period: 1 years

ClinicalTrials.Gov Trial: 

© 2014-2026 by CSAR

  • Spotify
  • Twitter Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
bottom of page